Last reviewed · How we verify
Meloxicam Nanocrystal Injection
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation. Used for Acute pain management, Rheumatoid arthritis, Osteoarthritis.
At a glance
| Generic name | Meloxicam Nanocrystal Injection |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | NSAID (Nonsteroidal Anti-inflammatory Drug) |
| Target | COX-1 and COX-2 (Cyclooxygenase enzymes) |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Rheumatology, Inflammation |
| Phase | Phase 3 |
Mechanism of action
Meloxicam selectively inhibits COX-2 and COX-1 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The nanocrystal formulation enhances bioavailability and allows for parenteral (injection) administration, providing faster onset of action compared to oral formulations. This mechanism makes it effective for treating inflammatory and pain conditions.
Approved indications
- Acute pain management
- Rheumatoid arthritis
- Osteoarthritis
- Ankylosing spondylitis
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Abdominal pain
- Cardiovascular events (myocardial infarction, stroke)
- Renal impairment
- Hypertension
Key clinical trials
- Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects (PHASE1)
- Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |